US 12,186,321 B2
Liquid oral formulations for sildenafil
Jinal Pandya, Unjha (IN); Sandip P. Mehta, Ahmadabad (IN); Manish Umrethia, Ahmedabad (IN); Jayanta Kumar Mandal, Ahmedabad (IN); and Hiren Pansuriya, Ahmedabad (IN)
Assigned to LIQMEDS WORLDWIDE LIMITED, Hayes (GB)
Filed by LIQMEDS WORLDWIDE LIMITED, Hayes (GB)
Filed on Apr. 4, 2024, as Appl. No. 18/626,876.
Application 18/626,876 is a continuation of application No. 18/365,266, filed on Aug. 4, 2023, granted, now 12,005,062.
Application 18/365,266 is a continuation of application No. 17/823,546, filed on Aug. 31, 2022, granted, now 11,759,468, issued on Sep. 19, 2023.
Application 17/823,546 is a continuation of application No. 16/957,894, granted, now 11,464,778, issued on Oct. 11, 2022, previously published as PCT/IB2018/001462, filed on Dec. 24, 2018.
Claims priority of application No. 201721046640 (IN), filed on Dec. 26, 2017; and application No. 201821012438 (IN), filed on Apr. 2, 2018.
Prior Publication US 2024/0245689 A1, Jul. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/08 (2006.01); A61K 31/4985 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/519 (2013.01) [A61K 9/08 (2013.01); A61K 31/4985 (2013.01); A61K 47/10 (2013.01)] 30 Claims
 
1. A ready-to-use liquid oral formulation, comprising:
about 10 mg/mL of sildenafil, as sildenafil citrate having a d90 particle size of from about 10 microns to about 100 microns; and
one or more pharmaceutically acceptable excipients comprising a wetting agent comprising ethanol, glycerin, propylene glycol, or a combination thereof in an amount of from about 100 to about 1,000 mg/mL.